Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02629809
Title Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab

Ibrutinib + Obinutuzumab

Ibrutinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST